We are the global leader in superficial and deep regional hyperthermia systems, developed as an adjunct solution, for the treatment of solid cancer tumors. Pyrexar RF uses non-ionizing radiation to excite surrounding cellular tissue to "fever" temperatures to increase effectiveness when used with radiotherapy.
Pyrexar Medical formed to take on the fight against cancer. We purchased the Hyperthermia product line from BSD Medical in April 2015. We plan to support the existing BSD-500 and BSD-2000 customers, continue to make product improvements, support the growth of Thermal Oncology, and spread the word about this amazing cancer therapy.
In the delicate micro-environment of a cancer cell, heat can lead to direct cell death, shrinking tumor size for easier surgical resection.
Very low to no toxicity is often reported when administering hyperthermia. There is no known toxicity build-up from multiple treatments.
Increased blood flow and perfusion at the tumor site promote oxygenation, increasing radiosensitivity.
A phase III clinical study shows an increased survival benefit when hyperthermia was added to traditional therapies.
Hyperthermia, in combination with Radiotherapy, will inhibit the DNA repair cycle of radiation-damaged cancer cells.
Tumor cells express heat shock proteins when exposed to hyperthermic temperatures allowing tumor-specific antigens to reach the immune system.